

through healthy human skin after 24 hours was 0.26% of a dose and a skin depot containing 4.9% of the dose was formed.

References.

- Juzeniene A, *et al.* Topical application of 5-aminolevulinic acid, methyl 5-aminolevulinate and hexyl 5-aminolevulinate on normal human skin. *Br J Dermatol* 2006; **155**: 791–9.

Uses and Administration

5-Aminolevulinic acid is a naturally occurring haem precursor that is metabolised in the body to protoporphyrin IX, a photosensitiser, and then to haem. It has been formulated for topical use in photodynamic therapy (see under Porphyrin Sodium, p.764). It is used to treat actinic keratoses and basal cell carcinoma (see below). Aminolevulinic acid hydrochloride is applied topically as a 20% solution in the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. This is followed, 14 to 18 hours later, by illumination with blue wavelength light sufficient to supply a dose of 10 J/cm². Treatment may be repeated once after 8 weeks if necessary.

Methyl aminolevulinate hydrochloride is a derivative of 5-aminolevulinic acid that is applied topically for the treatment of non-hyperkeratotic, non-pigmented actinic keratoses of the face or scalp when other therapies are considered inappropriate. It is also used for the treatment of superficial and/or nodular basal cell carcinoma unsuitable for other therapies. In some countries, methyl aminolevulinate is licensed for the treatment of Bowen's disease (squamous cell carcinoma *in situ*) when surgical excision is inappropriate. A cream containing the equivalent of 16% methyl aminolevulinate is applied to the lesions and covered with an occlusive dressing. After 3 hours the cream is removed and the lesions are exposed to red wavelength light in a dose of 75 J/cm²; exposure to the cream for more than 4 hours should be avoided. For actinic keratoses, one session of photodynamic therapy is given, and again after 3 months if necessary. For basal cell carcinoma or Bowen's disease two sessions are given a week apart.

Patients should avoid sunlight or bright light sources for about 2 days after application.

Hexaminolevulinate hydrochloride is used as a diagnostic agent for the detection of bladder cancer (p.659), and is under investigation for the photodynamic therapy of bladder cancer.

Malignant neoplasms. The use of topical aminolevulinic acid or methyl aminolevulinate in the photodynamic therapy (PDT) of actinic keratosis and basal cell carcinoma (p.673) has been reviewed.^{1–5} Both aminolevulinic acid and methyl aminolevulinate are considered to be effective in clearing non-hyperkeratotic actinic keratoses of the face and scalp, with response rates comparable to topical 5-fluorouracil and cryotherapy; cosmetic response is superior to that with cryotherapy.^{6,7} More than 80% of lesions cleared completely after 2 treatments with aminolevulinic acid PDT; a recurrence rate of 19% was reported over 12 months.⁸ Single treatment with methyl aminolevulinate is effective for thin lesions but thicker, non-responsive lesions may benefit from repeated treatment.⁹ No significant differences in efficacy were seen between PDT with aminolevulinic acid or methyl aminolevulinate in the treatment of scalp actinic keratosis.¹⁰ Aminolevulinic acid is considered as effective as cryotherapy but with superior healing and cosmetic results for superficial basal cell carcinoma; it is less effective for nodular disease.⁹ Intraleisional use has been investigated to improve penetration of the photosensitiser, with good preliminary results.¹¹ Methyl aminolevulinate topical PDT may be preferable for difficult-to-treat basal cell carcinoma.^{12,13} Aminolevulinic acid is as effective in Bowen's disease (squamous cell carcinoma *in situ*) as cryotherapy or 5-fluorouracil, but with fewer adverse effects.⁶ Topical methyl aminolevulinate PDT was more effective and cosmetically acceptable compared with topical 5-fluorouracil for pre-malignant skin disease in a small study in organ transplant recipients.¹⁴

PDT using oral 5-aminolevulinic acid as the photosensitiser, at doses of 30 or 60 mg/kg, has been used to treat Barrett's oesophagus, which is a major risk factor for oesophageal adenocarcinoma (p.664).^{15,16} A small study found similar clinical responses with low-dose (30 mg/kg) and high-dose (60 mg/kg) aminolevulinic acid protocols.¹⁷ Good long-term results have been reported with aminolevulinic acid PDT in patients with early neoplasia or high-grade intraepithelial neoplasia.¹⁸

Aminolevulinic acid is also under investigation for the photodynamic detection and treatment of brain tumours (p.660).¹⁹ It has also been used for the fluorescence detection of pleural malignancies.²⁰

An intravesical solution of aminolevulinic acid has been instilled for the detection²¹ and management²² of superficial bladder cancer (p.659). Hexaminolevulinate is used for the diagnosis of bladder cancer, and it appears to be more effective than standard white light cystoscopy.^{13,25}

A topical application of 5-aminolevulinic acid 3% has been tried in the treatment of cervical intraepithelial neoplasia, with poor response.²⁶

- Ormerod D, Jarvis B. Topical aminolevulinic acid HCl photodynamic therapy. *Am J Clin Dermatol* 2000; **1**: 133–9.
- Gupta AK, Ryder JE. Photodynamic therapy and topical aminolevulinic acid: an overview. *Am J Clin Dermatol* 2003; **4**: 699–708.
- Siddiqui MAA, *et al.* Topical methyl aminolevulinate. *Am J Clin Dermatol* 2004; **5**: 127–37.
- Marmur ES, *et al.* A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. *Dermatol Surg* 2004; **30**: 264–71.
- Lehmann P. Methyl aminolevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. *Br J Dermatol* 2007; **156**: 793–801.
- Morton CA, *et al.* Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. *Br J Dermatol* 2002; **146**: 552–67. Also available at: http://www.bad.org.uk/healthcare/guidelines/topical_photodynamic_therapy.pdf (accessed 09/05/08).
- Morton C, *et al.* AKTION Investigators. Intraindividual, right-left comparison of topical methyl aminolevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. *Br J Dermatol* 2006; **155**: 1029–36.
- Tsichen EH, *et al.* Phase IV ALA-PDT Actinic Keratosis Study Group. Photodynamic therapy using aminolevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. *Br J Dermatol* 2006; **155**: 1262–9.
- Tarstedt M, *et al.* A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)–PDT in actinic keratosis of the face and scalp. *Acta Derm Venereol* 2005; **85**: 424–8.
- Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolevulinic acid methylester with topical 5-aminolevulinic acid photodynamic therapy for extensive scalp actinic keratosis. *Br J Dermatol* 2007; **157**: 87–91.
- Cappugi P, *et al.* New proposal for the treatment of nodular basal cell carcinoma with intraleisional 5-aminolevulinic acid. *J Chemother* 2004; **16**: 491–3.
- Horn M, *et al.* Topical methyl aminolevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. *Br J Dermatol* 2003; **149**: 1242–9.
- Vinciullo C, *et al.* Photodynamic therapy with topical methyl aminolevulinate for 'difficult-to-treat' basal cell carcinoma. *Br J Dermatol* 2005; **152**: 765–72.
- Perrett CM, *et al.* Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. *Br J Dermatol* 2007; **156**: 320–8.
- Ackroyd R, *et al.* Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. *Gut* 2000; **47**: 612–17.
- Barr H. Barrett's esophagus: treatment with 5-aminolevulinic acid photodynamic therapy. *Gastrointest Endosc Clin N Am* 2000; **10**: 421–37.
- Kelly CJ, *et al.* Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. *Surg Endosc* 2004; **18**: 452–8.
- Pech O, *et al.* Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. *Gastrointest Endosc* 2005; **62**: 24–30.
- Friesen SA, *et al.* 5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review). *Int J Oncol* 2002; **21**: 577–82.
- Baas P, *et al.* Fluorescence detection of pleural malignancies using 5-aminolevulinic acid. *Chest* 2006; **129**: 718–24.
- Zaak D, *et al.* Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. *Cancer* 2002; **95**: 1234–8. Correction. *ibid.*; 2580.
- Kriegmair M, *et al.* Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. *Br J Urol* 1996; **77**: 667–71.
- Anonymous. Hexyl aminolevulinate: 5-ALA hexylester, 5-ALA hexylester, aminolevulinic acid hexyl ester, hexaminolevulinate, hexyl-5-aminolevulinate, P 1206. *Drugs R D* 2005; **6**: 235–8.
- Jocham D, *et al.* Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. *J Urol (Baltimore)* 2005; **174**: 862–6.
- Frampton JE, Plosker GL. Hexyl aminolevulinate: in the detection of bladder cancer. *Drugs* 2006; **66**: 571–8.
- Barnett AA, *et al.* A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolevulinic acid for the treatment of cervical intraepithelial neoplasia. *Int J Cancer* 2003; **103**: 829–32.

Skin disorders. 5-Aminolevulinic acid has been used topically in the photodynamic therapy (PDT) of skin conditions such as psoriasis, recalcitrant viral warts, acne vulgaris, and cutaneous T-cell lymphoma.¹ Variable results have been reported with this therapy in patients with plaque psoriasis; in one study therapy was generally well-tolerated,² but in the other all patients reported stinging or burning during irradiation.³ A study comparing 5-aminolevulinic acid and methyl aminolevulinate for PDT of acne found both to be equally effective, although methyl aminolevulinate seemed to be better tolerated.⁴ Topical methyl aminolevulinate-based PDT has been found to be effective in the treatment

of facial acne vulgaris.^{5,6} PDT with 5-aminolevulinic acid has been reported to significantly improve an infected leg ulcer resistant to conventional therapies.⁷ A topical 10% solution has been used with intraurethral PDT to treat condylomata acuminata.⁸

- Ibbotson SH. Topical 5-aminolevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. *Br J Dermatol* 2002; **146**: 178–88.
- Smits T, *et al.* A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolevulinic acid-photodynamic therapy in patients with psoriasis. *Br J Dermatol* 2006; **155**: 429–36.
- Radakovic-Fijan S, *et al.* Topical aminolevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. *Br J Dermatol* 2005; **152**: 279–83.
- Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. *J Am Acad Dermatol* 2006; **54**: 647–51.
- Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolevulinate: a blinded, randomized, controlled trial. *Br J Dermatol* 2006; **154**: 969–76.
- Hörfelt C, *et al.* Topical methyl aminolevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. *Br J Dermatol* 2006; **155**: 608–13.
- Clayton TH, Harrison PV. Photodynamic therapy for infected leg ulcers. *Br J Dermatol* 2007; **156**: 384–5.
- Wang XL, *et al.* Topical 5-aminolevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. *Br J Dermatol* 2004; **151**: 880–5.

Preparations

Proprietary Preparations (details are given in Part 3)


Austria: Metvix; **Belg:** Metvix; **Cz:** Hexvix; MC 506; Metvix; **Denm.:** Metvix; **Fin:** Hexvix; Metvix; **Fr:** Metvixia; **Ger:** Metvix; **Gr:** Hexvix; **Ital:** Metvix; **Neth:** Hexvix; Metvix; **Norw:** Hexvix; Metvix; **NZ:** Metvix; **Port:** Gliolan; **Hexvix;** Metvix; **S.Afr:** Metvix; **Spain:** Metvix; **Swed:** Hexvix; Metvix; **Switz:** Metvix; **UK:** Metvix; Porphin; **USA:** Levulan Kerastick; Metvixia.

Amonafide (rINN)

Amonafide; Amonafidum; M-FA-142; Nafidimide; NSC-308847. 3-Amino-N-[2-(dimethylamino)ethyl]naphthalimide.

Амонафид

C₁₆H₁₇N₃O₂ = 283.3.
CAS — 69408-81-7.



Profile


Amonafide is a topoisomerase inhibitor. Amonafide malate is under investigation for the treatment of acute myeloid leukaemia. Amonafide hydrochloride has also been investigated, but studies were stopped due to serious adverse effects.

Amrubicin (USAN, rINN)

Amrubicin; Amrubicine; Amrubicinum; SM-5887. (+)-(7S,9S)-9-Acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)-oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione.

Амрубицин

C₂₅H₂₅NO₉ = 483.5.
CAS — 110267-81-7 (amrubicin); 110311-30-3 (amrubicin hydrochloride).



Profile

Amrubicin is a synthetic anthracycline derivative related to compounds such as doxorubicin (p.712). Amrubicin hydrochloride is used as an antineoplastic in the treatment of lung cancer, and is under investigation in the treatment of superficial bladder cancers, and lymphomas.

Preparations

Proprietary Preparations (details are given in Part 3)

Jpn: Calsed.

Amsacrine (BAN, USAN, pINN)

Acridinyl Anisidide; m-AMSA; Amsacrina; Amsacrinum; Amsakrini; Amsakrin; Cl-880; NSC-249992. 4'-(Acridin-9-ylamino)methanesulphon-m-anisidide.


Амсакрин

$C_{21}H_{19}N_3O_3S = 393.5$.

CAS — 51264-14-3.

ATC — L01XX01.

ATC Vet — QL01XX01.



Incompatibility. Amsacrine is incompatible with sodium chloride 0.9% injection and with other chloride-containing solutions,^{1,2} apparently because of the poor solubility of the hydrochloride salt in aqueous solution.² Amsacrine reacts with certain plastics.¹

1. D'Arcy PF. Reactions and interactions in handling anticancer drugs. *Drug Intell Clin Pharm* 1983; **17**: 532-8.
2. Trissel LA, et al. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. *Am J Hosp Pharm* 1990; **47**: 2525-8.

Adverse Effects, Treatment, and Precautions

For a general outline see Antineoplastics, p.635, p.639, and p.641.

Bone-marrow depression is usually dose-limiting and may be severe. The nadir of the white cell count has been reported at about 12 days after treatment, with recovery usually by the 25th day. Pancytopenia and haemorrhage may develop. Nausea and vomiting (mild to moderate), stomatitis (mild to life-threatening), rashes, and alopecia may occur. Grand mal seizures, renal dysfunction, hepatotoxicity, and cardiotoxicity have also been reported. Amsacrine is irritant: there may be phlebitis and local tissue necrosis particularly when given in high concentrations.

Amsacrine should be given with caution to patients with liver or kidney disease, who may require dosage adjustments.

Interactions

For a general outline of antineoplastic drug interactions, see p.642. Use with diuretics or nephrotoxic drugs such as the aminoglycosides may theoretically increase the risk of cardiotoxicity with amsacrine by precipitating hypokalaemia.

Pharmacokinetics

Amsacrine is poorly absorbed after oral doses. When given intravenously it has a reported terminal half-life of about 5 to 8 hours. It is metabolised in the liver and excreted primarily in the bile, mostly as metabolites. It is reported to be about 98% protein bound.

Uses and Administration

Amsacrine is an antineoplastic agent that appears to act by intercalation with DNA and inhibition of nucleic acid synthesis. It may also exert an action on cell membranes. Cells in G₂ or S phases may be most sensitive to its actions.

It is used for the induction and maintenance of remission in adult acute leukaemias, particularly acute myeloid leukaemia.

Amsacrine is prepared as a solution in lactic acid and dimethylacetamide, and is given, diluted in glucose 5%, by intravenous infusion over 60 to 90 minutes.

For the induction of remission, amsacrine may be given at a dose of 90 mg/m² daily for 5 to 8 days, depending on clinical response. Courses may be repeated at 2- to 4-week intervals according to response, and the dose may be increased to 120 mg/m² daily in subsequent courses if tolerated. Maintenance doses of 150 mg/m² as a single dose or divided over 3 consecutive days have been given every 3 to 4 weeks, adjusted if necessary according to response.

Complete blood counts should be performed regularly, and cardiac, liver, kidney, and CNS function should be monitored.

Doses should be reduced in patients with hepatic or renal impairment (see below).

References

1. Ghaddar HM, et al. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. *Leuk Lymphoma* 1996; **22**: 71-6.

2. Reman O, et al. Groupe d'Étude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte. Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia. *Hematol J* 2004; **5**: 123-9.
3. Sung WJ, et al. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. *Jpn J Clin Oncol* 2005; **35**: 612-16.
4. Horstmann MA, et al. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. *Haematologica* 2005; **90**: 1701-3.
5. Kessler T, et al. Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis. *Leuk Res* 2008; **32**: 491-4.

Administration in hepatic impairment. In moderate to severe hepatic impairment, dosage of amsacrine may need to be reduced by up to 50%. Some licensed product information recommends an initial reduction of 20 to 30%, to a dose between 60 and 75 mg/m² daily.

Administration in renal impairment. In moderate to severe renal impairment, dosage of amsacrine may need to be reduced by up to 50%. Some licensed product information recommends an initial reduction of 20 to 30%, to a dose between 60 and 75 mg/m² daily.

Preparations

Proprietary Preparations (details are given in Part 3)

Austral.: Amsidy; **Belg.:** Amsidine; **Canad.:** Amsa PD; **Cz.:** Amsidy†; **Denm.:** Amekrin; **Fin.:** Amekrin†; **Fr.:** Amsalyo†; **Ger.:** Amsidy†; **Ir.:** Amsidine; **Neth.:** Amsidine; **Swed.:** Amekrin; **Switz.:** Amsidy; **UK:** Amsidine.

Anastrozole (BAN, USAN, rINN) ⊗

Anastrotoli; Anastrozol; Anastrozolum; ICI-D1033; ZD-1033. 2,2'-(Dimethyl-2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(propionitrile); α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile.


Анастрозол

$C_{17}H_{19}N_5 = 293.4$.

CAS — 120511-73-1.

ATC — L02BG03.

ATC Vet — QL02BG03.



Adverse Effects, Treatment, and Precautions

The most frequent adverse effects are gastrointestinal disturbances including anorexia, nausea and vomiting, and diarrhoea; asthenia; hot flushes; dizziness; drowsiness; headache; and rash. Other reported effects include hair thinning, vaginal dryness or bleeding, myalgia, arthralgia, and bone fractures. Abnormalities in liver enzyme values, thromboembolism, and increases in total cholesterol, have occurred in some patients receiving anastrozole. Very rare cases of erythema multiforme, Stevens-Johnson syndrome, and allergic reactions (including angioedema, urticaria, and anaphylaxis) have occurred.

Reductions in bone mineral density can occur during use of anastrozole. Patients with or at risk of osteoporosis should therefore have their bone density assessed at the start of therapy and at regular intervals thereafter. Treatment or prophylaxis for osteoporosis should be started as appropriate and carefully monitored.

The use of anastrozole is contra-indicated in premenopausal women (particularly in pregnancy).

Effects on the liver. A case of acute hepatitis was attributed to anastrozole, 3 weeks after starting therapy.¹

1. de la Cruz L, et al. Severe acute hepatitis in a patient treated with anastrozole. *Lancet* 2007; **369**: 23-4.

Effects on the musculoskeletal system. In a series of 77 postmenopausal women treated with anastrozole for metastatic breast cancer, 12 complained of joint pains within 2 months of beginning therapy. Based on this experience and the incidence of arthralgia reported during clinical studies, the authors estimated

that arthralgia occurs in 10 to 15% of patients treated with anastrozole, possibly as a result of the very low oestrogen concentrations achieved.¹

Adjuvant anastrozole therapy for postmenopausal women with early breast cancer was associated with accelerated bone loss, but the risk appeared to be confined to those with osteopenia at baseline.² These patients should be assessed for the risk of osteoporosis before starting therapy, and the decision to treat should be made on an individual basis.³

1. Donnellan PP, et al. Aromatase inhibitors and arthralgia. *J Clin Oncol* 2001; **19**: 2767.
2. Eastell R, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18253230. *J Clin Oncol* 2008; **26**: 1051-8.
3. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. *J Clin Oncol* 2006; **24**: 5305-12.

Pharmacokinetics

Anastrozole is rapidly and almost completely absorbed from the gastrointestinal tract after oral doses, with peak plasma concentrations within about 2 hours. Food decreases the rate of absorption, though this is not considered clinically significant. Anastrozole is 40% bound to plasma proteins. It is metabolised in the liver, and excreted in urine, chiefly as metabolites. The terminal plasma elimination half-life is about 40 to 50 hours, and steady-state concentrations are achieved after about 7 days in patients receiving once-daily doses.

Uses and Administration

Anastrozole is a potent and selective nonsteroidal inhibitor of the aromatase (oestrogen synthetase) system, which converts adrenal androgens to oestrogens in peripheral tissue. It is used in the treatment of advanced or locally advanced breast cancer, and as adjuvant treatment in early breast cancer (p.661), in postmenopausal women in an oral dose of 1 mg daily. Responses are unlikely in patients with oestrogen receptor-negative disease. Adjuvant therapy may be continued for up to 5 years, although the optimum duration is uncertain.

References

1. Bonnetterre J, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. *J Clin Oncol* 2000; **18**: 3748-57.
2. Nabholz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. *J Clin Oncol* 2000; **18**: 3758-67.
3. The ATAC (Arimidex, Tamoxifen Alone or in Combination) trialists' group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002; **359**: 2131-9.
4. Wellington K, Faulds DM. Anastrozole in early breast cancer. *Drugs* 2002; **62**: 2483-90.
5. Baum M, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. *Cancer* 2003; **98**: 1802-10.
6. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. *Lancet* 2005; **365**: 60-2.
7. Jakesz R, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. *Lancet* 2005; **366**: 455-62.
8. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. *Lancet Oncol* 2006; **7**: 633-43.
9. Jonat W, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. *Lancet Oncol* 2006; **7**: 991-6. Correction. *ibid.* 2007; **8**: 6.
10. Jakesz R, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. *J Natl Cancer Inst* 2007; **99**: 1845-53. Correction. *ibid.* 2008; **100**: 226.
11. Forbes JP, et al. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. *Lancet Oncol* 2008; **9**: 45-53.

Endometriosis. In a small, open-label study,¹ oral anastrozole 1 mg, given daily with a low-strength oral contraceptive for 6 months, reduced pelvic pain scores in women with refractory endometriosis (p.2091). Adverse effects were mild, although most patients had breakthrough bleeding, which exacerbated pain. The authors supposed that a higher dose of oral contraceptive should be considered in future studies.

In a small pilot study of patients with rectovaginal endometriosis,² anastrozole 250 micrograms was given vaginally once daily